CEO, Novo Genomics

Dr. Abdulelah Alhawsawi, is the CEO of Novo Genomics. Novo Genomic’s Vision is to be: regionally trusted, globally recognized biotechleader in the field of genomics & multiomics.

Dr. Alhawsawi the Former – founding Director General of the Saudi Patient Safety Center (SPSC), and MOH Advisor on Patient Safety. Heled the efforts to establishing SPSC as a WHO Collaborating Center for patient safety policies and strategies (1 of only 5 WHOcc worldwide in this field). He holds Dual Certified Boards (American – Canadian) of general surgery with sub-specialty in Transplant and Hepatobiliary Surgery.

He is a consultant to several national and international quality and safety organizationsand recently became a board member and Vice President of the Global Sepsis Alliance (GSA) as well as a Board member of Joint Commission Resources Board. He was part of the Expert Panel onthe 3rd Global Patient Safety Challenge of the WHO and chaired the Organizing Committee for the 4th Global Ministerial Summit on Patient Safety in Jeddah, Saudi Arabia in 2019.

Dr. Alhawsawi has helped introduce Patient Safety as a G20 priority in the 2020 G20 of Saudi Arabia.Currently, Dr. Alhawsawi is part of the WHO’s Global Patient Safety Action Plan Taskforce.